Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
Status:
Enrolling by invitation
Trial end date:
2024-07-29
Target enrollment:
Participant gender:
Summary
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants)
or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure
that will enroll pediatric participants (6-17 years of age) with FC or IBS-C who completed
study intervention in studies LIN-MD-62, LIN-MD-63, orLIN-MD-64 based on the individual study
criteria.